Clinical trials of a new drug that promotes tooth growth have started in Japan. This was reported by Zamin.uz.
This drug, developed by scientists at Kyoto University, is expected to open a new chapter in medicine. It helps teeth to naturally regrow and is a study that has not been conducted in any country before.
The trials began in 2024 and involve 30 male participants aged between 30 and 64. The results obtained could change approaches not only in dentistry but also in the entire field of medicine.
This drug is based on a special antibody called USAG-1, which is a factor limiting tooth growth in mammals. Specialists at Kyoto University have found a method to block the interaction between the USAG-1 antibody and bone morphogenetic protein.
This process allows the regeneration of dental tissues and the growth of new teeth. The drug was developed using monoclonal antibodies, which were previously mainly used in oncology.
The safety of the new drug was confirmed in animal tests. Therefore, permission was granted for clinical trials in humans.
Professor Katsu Takahashi, head of the dentistry and maxillofacial surgery department at Kitano Hospital, emphasized the importance of determining whether this process leads to complete regeneration. If the trials are successful, treatment for children suffering from congenital adentia is planned to begin in 2026.
This will be a major breakthrough in dentistry. In the future, by 2030, a drug that helps tooth growth and is accessible to the general public is planned to be developed.
If this goal is achieved, a new era in medicine is expected to begin.
